HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival

Table 2 Predictors of statin use among kidney transplant recipients

Variable	Crude Odds Ratio (95% CI)*	p-value	Adjusted Odds Ratio (95% CI)	p-value
Age at transplant (per year)	1.02 (1.007 - 1.032)	0.002	1.02 (1.00 - 1.04)	0.005
Body Mass Index	1.05 (1.02 - 1.09)	0.002	1.08 (1.03-1.13)	0.001
Sex	0.96 (0.68 - 1.35)	0.82	1.12 (0.71-1.76)	0.63
Race	1.51 (0.95-2.40)	0.09	1.23 (0.67-2.24)	0.50
MI	1.85 (1.00-3.42)	0.05	N/A
Diabetes with complications	1.61 (1.05-2.47)	< 0.0001	N/A
Alkaline phosphatase (per U/L)	0.99 (0.99 - 0.99)	0.02	0.99(0.99-0.99)	0.017
CMV IgG positive	0.63 (0.43 - 0.93)	0.02	0.64 (0.39 - 1.05)	0.08
Triglycerides (per 10 mg/dL)	1.004 (1.002 - 1.005)	< 0.0001	N/A
Cholesterol	1.01 (1.005-1.014)	< 0.0001	1.01 (1.005-1.015)	< 0.001
Previous Transplant	0.68 (0.45-1.04)	0.07	N/A

ISSN: 1471-2369